Last $1.76 USD
Change Today -0.01 / -0.56%
Volume 287.0K
PIP On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

pharmathene inc (PIP) Snapshot

Open
$1.73
Previous Close
$1.77
Day High
$1.77
Day Low
$1.71
52 Week High
09/10/14 - $2.59
52 Week Low
07/23/14 - $1.19
Market Cap
99.3M
Average Volume 10 Days
127.0K
EPS TTM
$-0.19
Shares Outstanding
56.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMATHENE INC (PIP)

pharmathene inc (PIP) Related Businessweek News

No Related Businessweek News Found

pharmathene inc (PIP) Details

PharmAthene, Inc., a biodefense company, develops and commercializes medical countermeasures against biological and chemical threats in the United States. Its product candidates include SparVax, a recombinant protective antigen anthrax vaccine for post-exposure prophylaxis in conjunction with antibiotics and general use prophylaxis; Valortim, a human monoclonal antibody to protect against and treat human inhalational anthrax; and recombinant butyrylcholinesterase bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds comprising nerve gases and pesticides. The company serves the United States Department of Defense, Chemical Biological Medical Systems, Biomedical Advanced Research and Development Authority, the National Institute of Allergy and Infectious Diseases, and the National Institute of Health. It has collaboration with Bristol-Myers Squibb for developing Valortim; and strategic alliance with Nanotherapeutics, Inc. to develop biodefense programs. The company is headquartered in Annapolis, Maryland.

52 Employees
Last Reported Date: 03/11/14

pharmathene inc (PIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $456.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $318.0K
Senior Vice President of Regulatory Affairs a...
Total Annual Compensation: $326.4K
Senior Vice President of Policy & Government ...
Total Annual Compensation: $294.4K
Compensation as of Fiscal Year 2013.

pharmathene inc (PIP) Key Developments

PharmAthene, Inc. Wins a Contract of up to $28.1 Million to Develop Next Generation Thermostable Anthrax Vaccine

PharmAthene, Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next generation anthrax vaccine based on the Company's proprietary rPA anthrax vaccine technology platform. Various government agencies, including the Institute of Medicine, have acknowledged the need to develop and stockpile next generation anthrax vaccines employing modern vaccine technology, which offer the potential for improved safety, convenience, cost-effectiveness, and more rapid immunity.

PharmAthene, Inc. Announces Non-Clinical Animal Data from its SparVax(R) Anthrax Vaccine Program

PharmAthene, Inc. announced that recent non-clinical animal data from its SparVax(R) anthrax vaccine program were presented at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. In the latest anthrax challenge study, three groups of twenty NZW rabbits were vaccinated with SparVax(R) via intramuscular injection, on study days 0 and 28 at doses of 3, 9, or 27 micrograms. In addition, twenty animals were vaccinated with BioThrax(R), the currently-licensed anthrax vaccine. On the 70(th) day of the study, the NZW rabbits were challenged with a lethal dose of aerosolized anthrax spores. The study results demonstrated that SparVax(R) was statistically non-inferior compared to BioThrax(R) and provided equivalent protection against lethal aerosol anthrax challenge at the proposed human equivalent dose. In addition, the toxin neutralization (TNA) data showed that the neutralizing antibody titers for SparVax(R) were 1.5 to 2-fold higher than BioThrax(R) at all observed post-immunization time points, and statistically higher on the day before anthrax challenge.

PharmAthene,Inc. and Nanotherapeutics, Inc. Form Strategic Alliance to Advance Biodefense Programs

PharmAthene Inc. and Nanotherapeutics, Inc. announced that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans. PharmAthene's pipeline of products to prevent and treat emerging infectious diseases and biodefense threats fits well with Nanotherapeutics manufacturing and development capabilities and within the objectives of the Department of Defense (DoD) mandate for Advance Development and Manufacturing program. The agreement provides for the selection of various products from either company's portfolios and the ability to move forward with respect to funding proposals, research and development. The first Alliance Product on which the Companies will focus is PharmAthene's rBChE bioscavenger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides. Specifically, the Companies will capitalize on Nanotherapeutics' extensive manufacturing and formulation capabilities in order to progress PharmAthene's second generation approach to the rBChE bioscavenger, which utilizes a cell-based expression system (the PER.C6(R) human cell line) that is expected to yield distinct manufacturing and cost advantages over traditional and developmental approaches, including higher production yields, lower production costs and a more streamlined path to FDA licensure for the product. DoD has highlighted the need for chemical bioscavenger products to enhance readiness and protect the warfighter potentially enabling near-term partnering opportunities for the Alliance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIP:US $1.76 USD -0.01

PIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $70.14 USD +0.08
Bayer AG €112.78 EUR +2.36
Emergent Biosolutions Inc $22.62 USD +0.27
Protalix BioTherapeutics Inc 832.20 0.00
View Industry Companies
 

Industry Analysis

PIP

Industry Average

Valuation PIP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.7x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMATHENE INC, please visit www.pharmathene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.